Jax DiEugenio

Jax DiEugenio joined MJH Life Sciences in 2024, first as an editorial intern before transitioning into a full-time assistant editor for OncLive. A recent College of New Jersey graduate, Jax majored in Journalism/ Professional Writing with minors in Public Health and Anthropology. He is also pursuing a Master's Degree in Public Health, concentrating on health communications.

Articles

Dr Alderuccio on Loncastuximab Tesirine Plus Rituximab in High-Risk R/R Follicular Lymphoma

March 31st 2025

Juan P. Alderuccio, MD, discusses data from loxcastuximab tesirine plus rituximab in high-risk, relapsed/refractory follicular lymphoma.

Apraglutide/Ruxolitinib Provides Efficacy Benefit vs Ruxolitinib Alone in Refractory GI aGVHD

March 31st 2025

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Tislelizumab Plus Chemo Expands First-Line ESCC Treatment Paradigm

March 31st 2025

Nataliya Uboha, MD, PhD, discusses the benefits of expanding the first-line ESCC treatment paradigm with tislelizumab plus chemotherapy.

Orca-T Is Associated With Retrospective OS Improvement vs Post-Transplant Cyclophosphamide in Advanced Hematologic Malignancies

March 31st 2025

Orca-T was associated with a retrospective survival improvement vs post-transplant cyclophosphamide in advanced hematologic malignancies.

First-Line Acalabrutinib Plus BR Receives CHMP Recommendation for Mantle Cell Lymphoma

March 31st 2025

CHMP recommends EU approval of acalabrutinib plus chemoimmunotherapy for untreated mantle cell lymphoma.

CAN-2049 Displays Potential OS Benefit in Advanced NSCLC After Inadequate Response to Checkpoint Inhibitors

March 31st 2025

CAN-2049 plus prodrug and continued immune checkpoint inhibition showed a potential OS benefit in advanced non–small cell lung cancer.

Relacorilant Plus Nab-Paclitaxel Improves Survival in Platinum-Resistant Ovarian Cancer

March 31st 2025

Relacorilant plus nab-paclitaxel demonstrated improved PFS and OS in platinum-resistant ovarian cancer.

Tislelizumab Plus Chemo Receives Positive CHMP Opinion for ES-SCLC

March 31st 2025

The EMA’s CHMP recommended the approval of first-line tislelizumab plus chemotherapy for extensive-stage small cell lung cancer.

Multiple Myeloma Awareness Month: MGUS Recognition, Symptom Evaluation Drive Diagnosis

March 29th 2025

Jeffrey Zonder, MD, emphasizes the importance of identifying MGUS and evaluating nonspecific symptoms to improve the detection of multiple myeloma.

Dr Galsky on the Significance of the FDA Approval of Perioperative Durvalumab Plus Gemcitabine/Cisplatin for MIBC

March 28th 2025

Matthew Galsky, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy for patients with muscle-invasive bladder cancer.

Dr Ayoub on an AI Model to Enhance Interpretability of Morphologic Heterogeneity in Glioblastoma

March 28th 2025

Georges Ayoub, MD, MS, discusses how a supervised deep-learning model trained with expert-labeled data seeks to improve interpretability and diagnostic precision in glioblastoma morphological analysis.

Dr Chan on the FDA Approval of Cabozantinib for Pancreatic and Extra-Pancreatic Neuroendocrine Tumors

March 28th 2025

Jennifer Chan, MD, MPH, discusses the FDA approval of cabozantinib for previously treated, advanced well-differentiated (extra) pancreatic neuroendocrine tumors.

Study Reveals Subgroups of Patients With RCC Who May Have Durable Responses to Immunotherapy: With David A. Braun, MD, PhD

March 27th 2025

Dr Braun discusses molecular factors that contribute to exceptional immune checkpoint inhibition responses among patients with renal cell carcinoma.

Dr Rimm on How FDA-Approved IHC Tests Pose Reproducibility Challenges in Breast Cancer

March 27th 2025

David Rimm, MD, PhD, discusses how FDA-approved IHC assays may lack reproducibility in real-world settings in breast cancer.

Dr Bowman on the Role of Kidney Cancer Awareness in Earlier Detection and Improved Patient Outcomes

March 27th 2025

Alex Bowman, MD, discusses the need for early symptom recognition, genetic risk evaluation, and research support to improve RCC detection and outcomes.

Mentorship, Advocacy, and Work-Life Balance Are Key to Supporting Women in Oncology

March 27th 2025

Kelly E. McCann, MD, discusses mentorship, sponsorship, and work-life balance in oncology, highlighting strategies for supporting women in the field.

Tisotumab Vedotin Gains Japanese Approval for Advanced Cervical Cancer

March 27th 2025

Tisotumab vedotin has received Japanese approval for advanced cervical cancer following chemotherapy.

Itolizumab Misses Primary End Point in Acute GVHD but Shows Meaningful Improvements in Other Areas

March 27th 2025

The day-29 ORR and CR rate was not met with frontline itolizumab vs placebo in patients with acute graft-vs-host disease enrolled in the phase 3 EQUATOR trial.

Continued Development of T-Cell–Redirecting Therapies Remains at the Heart of Myeloma Research

March 27th 2025

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights advances in T-cell–redirecting therapies in the space.

Strong Mentorship Opportunities Support the Next Generations of Women in Lymphoma: With Chandler Park, MD; and Ann S. LaCasce, MD, MMSc

March 26th 2025

Drs Park and LaCasce discuss advancements in Hodgkin and non-Hodgkin lymphoma management, including efforts to reduce long-term toxicity.